Cencora, Inc. Common Stock (COR)

Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q4 2026), with revenue up 5.5% year on year to $...

Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.71 for the fourth quarter of fiscal 2026, compared to $(1.75) in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 21.4 percent to $4.66 in the fiscal fourth quarter. For fiscal year 2026, diluted GAAP EPS increased 125.5 percent to $17.95. For fiscal year 2026, adjusted diluted EPS increased 12.3 percent to $17.97.

Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility.

Healthcare distributor Cencora (NYSE:COR) will be announcing earnings results this Wednesday before the bell. Here’s what to look for. Cencora met analysts’ ...

BALA CYNWYD, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states.

Cencora has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to $341.69 per ...

Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.

Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal

Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi

Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.79% on an annualized basis producing an average annual return of 20.35%. Currently, Cencora has a market capitalization of $61.36 billion.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its pe...

Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of $60.51 billion.

These healthcare companies can actually benefit from inflation.

Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of $59.16 billion.